cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cerevel Therapeutics Holdings Inc
8 own
7 watching
Current Price
$34.96
$-0.36
(-1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,462.28M
52-Week High
52-Week High
41.46
52-Week Low
52-Week Low
19.86
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-0.12087912
iconMarket Capitalization5,462.28M
icon52-Week High41.46
icon52-Week Low19.86
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio-0.12087912
What does the Cerevel Therapeutics Holdings Inc do?
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cerevel Therapeutics Holdings Inc make?
News & Events about Cerevel Therapeutics Holdings Inc.
Ticker Report
27days ago
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) CEO N Anthony Coles sold 50,000 shares of the businesss stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $29.94, for a total transaction of $1,497,000.00. Following the...
Zolmax
2 months ago
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has earned a consensus recommendation of Moderate Buy from the ten analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event:...
Benzinga
2 months ago
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarterEPS results and filed for a mixed-securities shelf offering of up to $900 million. read more...
Zolmax
4 months ago
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has been given an average rating of Moderate Buy by the eight brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy ...
Frequently Asked Questions
Frequently Asked Questions
What is Cerevel Therapeutics Holdings Inc share price today?
plus_minus_icon
Can Indians buy Cerevel Therapeutics Holdings Inc shares?
plus_minus_icon
How can I buy Cerevel Therapeutics Holdings Inc shares from India?
plus_minus_icon
Can Fractional shares of Cerevel Therapeutics Holdings Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cerevel Therapeutics Holdings Inc stocks?
plus_minus_icon
What is today’s traded volume of Cerevel Therapeutics Holdings Inc?
plus_minus_icon
What is today’s market capitalisation of Cerevel Therapeutics Holdings Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cerevel Therapeutics Holdings Inc?
plus_minus_icon
What percentage is Cerevel Therapeutics Holdings Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cerevel Therapeutics Holdings Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$34.96
$-0.36
(-1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SUMMIT THERAPEUTICS INC
SUMMIT THERAPEUTICS INC
$3.14
$-0.74 (-19.07 %)
Telesis Bio Inc
Telesis Bio Inc
$2.03
$0.16 (8.56 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.55
$0.02 (0.23 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$116.10
$-1.64 (-1.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SUMMIT THERAPEUTICS INC
SUMMIT THERAPEUTICS INC
$3.14
$-0.74 (-19.07 %)
Telesis Bio Inc
Telesis Bio Inc
$2.03
$0.16 (8.56 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.55
$0.02 (0.23 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$116.10
$-1.64 (-1.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00